Apotex cleared of Amgen patent infringement in Florida

07-09-2016

Apotex cleared of Amgen patent infringement in Florida

Sebra / Shutterstock.com

The US District Court for the Southern District of Florida ruled yesterday that Apotex did not infringe Amgen patents centring on its biologic drug Neulasta (pegfilgrastim).


Apotex, Amgen, Neulasta, notice of commercial marketing, FDA, patent, biosimilar

LSIPR